Acute Leukemia French Association-Clinical Research
Acute Leukemia French Association-Clinical Research is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatment by gilteritinib in subjects ≥18 years of age with relapsed/refractory FLT3-mutated acute myeloid leukemia
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Latest update
- Estimated end
- Not reported
An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics
Sponsor Centre Hospitalier Universitaire De Nice
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Acute Leukemia French Association-Clinical Research?
The 2026-10-09 snapshot links Acute Leukemia French Association-Clinical Research to 3 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Acute Leukemia French Association-Clinical Research?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Acute Leukemia French Association-Clinical Research conducted?
The linked trials record locations in 1 country, including France. These are trial locations, not confirmed office locations or countries where Acute Leukemia French Association-Clinical Research delivered services.
What can this page tell me about Acute Leukemia French Association-Clinical Research's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Acute Leukemia French Association-Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Acute Leukemia French Association-Clinical Research